Gecacitinib before, during and after stem cell transplant for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if taking Gecacitinib before, during, and after a stem cell transplant helps patients with myelofibrosis. The goal is to see if the drug can improve transplant outcomes and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have primary myelofibrosis or myelofibrosis that started from polycythemia vera or essential thrombocythemia
- Your myelofibrosis is intermediate-risk or high-risk according to the DIPSS-plus scoring system
- You are scheduled to receive a stem cell transplant from a related or unrelated donor
- You are in generally good health (able to care for yourself and up and about more than half of the day)
- You are willing to switch from your current JAK inhibitor to Gecacitinib before the trial starts (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called Gecacitinib for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose cGVHD is not fully controlled or requires long-term steroids. It aims to see if Gecacitinib can help manage symptoms and reduce steroid use.
This trial tests whether the drug gecacitinib can help prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant in people with myelofibrosis, a rare bone marrow disorder.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This trial tests a new drug called Gecacitinib for people who have acute graft-versus-host disease (a serious complication after a stem cell transplant) that did not get better with the standard second-line treatment, ruxolitinib. The goal is to see if Gecacitinib can help control the GVHD.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.